A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > REGULATORY
REGULATORY
- MHLW Economic Affairs Chief Not Optimistic about Reaching 80% Generic Target
September 28, 2020
- AMED to Fund 9 More Company-Led COVID-19 Drug Projects Including StemRIM, Takeda
September 28, 2020
- MHLW Approves Rakuten’s Photoimmunotherapy, Takeda’s PARP Inhibitor, Gilead’s Jyseleca and More
September 28, 2020
- MHLW to Commence Research on Lasting COVID-19 Effects, Report Ready by March-End
September 28, 2020
- MHLW to Set Up Study Group to Investigate Formulary Initiatives at Hospitals: Pharmaceutical Management Director
September 25, 2020
- MHLW Explains Budget Request to LDP Lawmakers, Members Vigilant about Handling of Price Survey Results
September 25, 2020
- MHLW to Request Budgets for Survey on Prescribing Status, Safety of COVID-19 Meds Using MID-NET Database
September 25, 2020
- Health Minister Ready to Discuss Telemedicine Rollout, but Wants to Ensure Peace of Mind for Patients
September 24, 2020
- PMDA to Continue Remote GCP/Compliance Inspections through End of March 2021
September 24, 2020
- Japan’s COVAX Participation Meant to Confirm Importance of Global Access to Vaccines: Minister
September 23, 2020
- MHLW Grants Orphan Status to 5 APIs
September 23, 2020
- HPV Vaccine Advocate Junko Mihara Picked as Vice MHLW Chief
September 23, 2020
- MHLW Panel Members Call for Special Consideration for Pricing of “Specific-Use Drugs”
September 18, 2020
- MHLW Panel Determines Unmet Medical Needs for 10 Drugs at Its 1st Online Meeting
September 18, 2020
- Health Minister Vows to Gauge Impact on Medical Institutions in Discussing Off-Year Re-Pricing
September 18, 2020
- New Japan PM Sticks to Abe’s Goal to Secure Coronavirus Vaccines for Whole Population by H1 2021
September 17, 2020
- Ex-Health Minister Tamura Comes Back as MHLW Chief
September 16, 2020
- Japan Inks COVAX Pact with Optional Arrangement, Commits 17.2 Billion Yen Upfront
September 16, 2020
- New Vice Health Minister Aiming to Get Coronavirus Drugs and Vaccines to Japanese People “as Quickly as Possible”
September 16, 2020
- MHLW Panel Allows Osaka Univ. Hospital to Continue JANP Study, Requires Report by Year End: Data Scandal
September 15, 2020
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…